



THW

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10593261            |
| Filing Date            | 2007-07-11          |
| First Named Inventor   | Lars Michael Larsen |
| Art Unit               | 1614                |
| Examiner Name          |                     |
| Attorney Docket Number | LARSEN=5            |

**U.S.PATENTS**

| Examiner Initial* | Cite No | Patent Number | Kind Code <sup>1</sup> | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|---------------|------------------------|------------|---|--|
| /ZF/              | 1       | 5552369       |                        | 1996-09-03 | FINDEISEN et al.                                |  |
|                   | 2       | 5624949       |                        | 1997-04-29 | William E. HEATH Jr. et al.                     |  |
|                   | 3       | 5674862       |                        | 1997-10-07 | William E. HEATH Jr. et al.                     |  |
|                   | 4       | 5698578       |                        | 1997-12-16 | William E. HEATH Jr. et al.                     |  |
|                   | 5       | 5710145       |                        | 1998-01-20 | Gaey Lowell ENGEL et al.                        |  |
|                   | 6       | 5824685       |                        | 1998-10-20 | Peter A. CAMPOCHIARO et al.                     |  |
|                   | 7       | 6015807       |                        | 2000-01-18 | Gaey Lowell ENGEL et al.                        |  |
| ↓                 | 8       | 6114320       |                        | 2000-09-05 | Lloyd P. AIELLO et al.                          |  |

If you wish to add additional U.S. Patent citation information please click the Add button.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10593261            |
| Filing Date            | 2007-07-11          |
| First Named Inventor   | Lars Michael Larsen |
| Art Unit               | 1614                |
| Examiner Name          |                     |
| Attorney Docket Number | LARSEN=5            |

**U.S.PATENT APPLICATION PUBLICATIONS**

| Examiner Initial* | Cite No | Publication Number | Kind Code <sup>1</sup> | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| /ZF/              | 1       | 20030032078        | A1                     | 2003-02-13       | Gabriel H. TRAVIS                               |  |

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

| Examiner Initial* | Cite No | Foreign Document Number <sup>3</sup> | Country Code <sup>2</sup> | Kind Code <sup>4</sup> | Publication Date | Name of Patentee or Applicant of cited Document   | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T <sup>5</sup>           |
|-------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|--|--------------------------|
| /ZF/              | 1       | 2005107707                           | WO                        | A1                     | 2005-11-17       | Allergan, Inc.                                    |  | <input type="checkbox"/> |
|                   | 2       | 02080936                             | WO                        | A1                     | 2002-10-17       | Ortho McNeil Pharmaceutical, Inc.                 |  | <input type="checkbox"/> |
|                   | 3       | 2005058304                           | WO                        | A1                     | 2005-06-30       | Cortical Pty Ltd.                                 |  | <input type="checkbox"/> |
|                   | 4       | 03104178                             | WO                        | A1                     | 2003-12-18       | Cortical Pty Ltd.                                 |  | <input type="checkbox"/> |
|                   | 5       | 02080935                             | WO                        | A1                     | 2002-10-17       | Ortho McNeil Pharmaceutical, Inc.                 |  | <input type="checkbox"/> |
|                   | 6       | 03097052                             | WO                        | A2                     | 2003-11-27       | Celgene Corporation                               |  | <input type="checkbox"/> |
| ↓                 | 7       | 99058126                             | WO                        | A1                     | 1999-11-18       | The Endowment for Research in Human Biology, Inc. |  | <input type="checkbox"/> |

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10593261            |
| Filing Date            | 2007-07-11          |
| First Named Inventor   | Lars Michael Larsen |
| Art Unit               | 1614                |
| Examiner Name          |                     |
| Attorney Docket Number | LARSEN=5            |

|      |    |            |    |    |            |                                |  |
|------|----|------------|----|----|------------|--------------------------------|--|
| /ZF/ | 8  | 02072003   | WO | A2 | 2002-09-19 | Tomas HAGSTROM                 | <input type="checkbox"/>                     |
|      | 9  | 02085400   | WO | A1 | 2002-10-31 | Supergen, Inc.                 | <input type="checkbox"/>                     |
|      | 10 | 0198294    | WO | A2 | 2001-12-27 | Dupont Pharmaceuticals Company | <input type="checkbox"/>                     |
|      | 11 | 03004058   | WO | A1 | 2003-01-16 | Santen Pharmaceutical Co.      | Abstract <input checked="" type="checkbox"/> |
|      | 12 | 2005056010 | WO | A1 | 2005-06-23 | Allergan, Inc.                 | <input type="checkbox"/>                     |
|      | 13 | 2005011741 | WO | A2 | 2005-02-10 | Allergan, Inc.                 | <input type="checkbox"/>                     |
|      | 14 | 03082081   | WO | A2 | 2003-10-09 | Maxim Pharmaceuticals, Inc.    | <input type="checkbox"/>                     |
| ↓    | 15 | 0522226    | EP | A1 | 1993-01-13 | Ciro COSTAGLIOLA               | <input type="checkbox"/>                     |

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

|                    |         |  |                          |
|--------------------|---------|--|--------------------------|
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.          | T5                       |
| /ZF/               | 1       | PAUL A. SIEVING et al. "Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy", Proc. Nat. Acad. Sci. (USA), February 13, 2001, Vol. 98, No. 4, pages 1835-1840 | <input type="checkbox"/> |

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10593261            |
| Filing Date            | 2007-07-11          |
| First Named Inventor   | Lars Michael Larsen |
| Art Unit               | 1614                |
| Examiner Name          |                     |
| Attorney Docket Number | LARSEN=5            |

|      |    |   |                          |
|------|----|---|--------------------------|
| /ZF/ | 2  | ROXANA A. RADU et al., "Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration", Proc. Nat. Acad. Sci. (USA), April 15, 2003, Vol. 100, No. 8, pages 4742-4747 | <input type="checkbox"/> |
|      | 3  | JANET R. SPARROW, "Therapy for macular degeneration: Insights from acne", PNAS, April 15, 2003, Vol. 100, No. 8, pages 4353-4354  | <input type="checkbox"/> |
|      | 4  | G. B. ARDEN, "The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible", Br J Ophthalmol, 2001, Vol 85, pages 366-370   | <input type="checkbox"/> |
|      | 5  | LERMAN, S., "Ocular side effects of accutane therapy", Lens and Eye Toxicity Research, 1992, Vol. 9(3-4), pages 429-38.   | <input type="checkbox"/> |
|      | 6  | DEVIPRASAD R. GOLLAPALLI et al., "Specific inactivation of isomerohydrolase activity by 11-cis-retinoids", Science Direct, Biochimica et Biophysica Acta 1651 (2003) pages 93-101   | <input type="checkbox"/> |
|      | 7  | DEVIPRASAD R. GOLLAPALLI et al., "All-trans-retinyl Esters Are the Substrates for Isomerization in the Vertebrate Visual Cycle", Biochemistry, April 25, 2003, Vol. 42 pages 5809-5818  | <input type="checkbox"/> |
|      | 8  | DEVIPRASAD R. GOLLAPALLI et al., "RPE65 Operates in the Vertebrate Visual Cycle by Stereospecifically Binding All-trans-Retinyl Esters", Biochemistry, September 17, 2003, Vol. 42, pages 11824-11830                               | <input type="checkbox"/> |
|      | 9  | PAUL S. BERNSTEIN et al., "Mechanism of Action of Aromatic Amines That Short-Circuit the Visual Cycle", Biochemistry, 1986, Vol. 25, pages 3370-3377  | <input type="checkbox"/> |
|      | 10 | N DRASDO et al., "Effect of darkness on inner retinal hypoxia in diabetes" The Lancet, Vol. 359, June 29, 2002, pages 2251-2253   | <input type="checkbox"/> |
|      | 11 | ANETTE WINSTON et al., "Regulation of Isomerohydrolase Activity in the Visual Cycle", Biochemistry, February 3, 1998, Vol. 37, pages 2044-2050  | <input type="checkbox"/> |
| ↓    | 12 | G.B. ARDEN et al., "Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis", Vision Research, Vol. 38, 1998, pages 1723-1729   | <input type="checkbox"/> |

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10593261            |
| Filing Date            | 2007-07-11          |
| First Named Inventor   | Lars Michael Larsen |
| Art Unit               | 1614                |
| Examiner Name          |                     |
| Attorney Docket Number | LARSEN=5            |

|      |    |  |                                     |
|------|----|--|-------------------------------------|
| /ZF/ | 13 | ANNA WROBEL et al., "Antiangiogenic activity of agonist and antagonists of retinoid nuclear receptors", <i>Przeglad Dermatologiczny</i> , 1999, Vol. 86, No. 4, pages 339-346 (in Polish)    | <input checked="" type="checkbox"/> |
|      | 14 | MICHAEL F. MARMOR, et al., "Albipunctate Retinopathy with cone Dysfunction and no Abnormality in the RDH5 or RLBPI Genes", <i>Retina</i> 2003 United States, Vol. 23, Vol. 4, pages 543-546  | <input type="checkbox"/>            |
|      | 15 | B. M. CALISSENDORFF, "Retinal changes degeneration or side effects caused by etretinate therapy Tigason" <i>Klin. Mbl. Augenheilk.</i> , Vol. 194, 1989, pages 187-189 (in German)           | <input checked="" type="checkbox"/> |
|      | 16 | TSUTOMU OIKAWA et al., "Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo", <i>Europ J. of Pharmac.</i> , Vol. 249, 1993, pages 113-116 | <input type="checkbox"/>            |
| ↓    | 17 | SELIG HECHT et al., "Rod-Cone Dark Adaptation and Vitamin A", <i>Science, New Series</i> , Vol. 88, No. 2279, September 2, 1938, pages 219-221   | <input type="checkbox"/>            |
|      | 18 | JOHN E. DOWLING et al., "Vitamin a Deficiency and Night Blindness", <i>Proc. Natl. Acad. Sci. USA</i> Vol. 44, (1958) pages 648-661  | <input type="checkbox"/>            |
|      | 19 | RICHARD G. WELEBER et al., "Abnormal Retinal Function Associated with Isotretinoin Therapy for Acne", <i>Arch Ophthalmol</i> , Vol. 104, June 1986, pages 831-837                            | <input type="checkbox"/>            |
|      | 20 | H. MACLEAN et al., "Abnormal night vision with isotretinoin therapy for acne", <i>Clinical and Experimental Dermatol</i> , Vol. 20, page 86, January 1995,                                   | <input type="checkbox"/>            |
|      | 21 | ROSALIE K. CROUCH et al., "Retinoids and the Visual Process", <i>Photochem. Photobiol.</i> , Vol. 64, pages 613-621  | <input type="checkbox"/>            |
|      | 22 | F. T. FRAUNFELDER, et al., "Ocular Side Effects Possibly Associated with Isotretinoin Usage", <i>Am. J. Ophthalmol</i> , Vol. 132, 2001, pages 299-305                                       | <input type="checkbox"/>            |
| ↓    | 23 | WING C. LAW et al., "The Molecular Basis of Retinoic Acid Induced Night Blindness" <i>Biochem. Biophys. Res. Comm.</i> , Vol. 161, No. 2, pages 825-829                                      | <input type="checkbox"/>            |

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10593261            |
| Filing Date            | 2007-07-11          |
| First Named Inventor   | Lars Michael Larsen |
| Art Unit               | 1614                |
| Examiner Name          |                     |
| Attorney Docket Number | LARSEN=5            |

|      |    |  |                          |
|------|----|--|--------------------------|
| /ZF/ | 24 | BELINDA M. WELSH et al., "Night blindness precipitated by isotretinoin in the setting of hypovitaminosis A", Australas J Dermatol, Vol. 40, 1999, pages 208-210  | <input type="checkbox"/> |
|      | 25 | G. P. MOSS et al., "Nomenclature of Retinoids", Arch. Biochem., Biophys. Vol. 224, No. 2, July 15, 1983, pages 728-731   | <input type="checkbox"/> |
|      | 26 | BRAHMA P. SANI et al., "Structural Characteristics of Synthetic Retinoids", Meth. In Enzymology, Vol. 189, 1990, pages 43-59   | <input type="checkbox"/> |
|      | 27 | MICHAEL KLAUS, "Structure Characteristics of Natural and Synthetic Retinoids" Meth. In Enzymology, Vol. 189, (1990) pages 3-14   | <input type="checkbox"/> |
|      | 28 | M. I. DAWSON et al., "Synthetic Retinoic Acid Analogs: Handling and Characterization", Meth. In Enzymology, Vol. 189, , 1990, pages 15-43  | <input type="checkbox"/> |
|      | 29 | GREGORY M. ACLAND et al., "Gene therapy restores vision in a canine model of childhood blindness", Nature genetics, Vol. 28, May 2001, pages 92-95   | <input type="checkbox"/> |
|      | 30 | T. MICHAEL REDMOND et al., "Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle", Nature Genetics, Vol. 20, December 1998, pages 344-351   | <input type="checkbox"/> |
|      | 31 | PAUL S. BERNSTEIN et al., "The Specific Inhibition of 11-cis-Retinyl Palmitate Formation in the Frog Eye by Diaminophenoxypentane, An inhibitor of Rhodopsin Regeneration", Vision Res., Vol. 25, No. 6, 1985, pages 741-748 | <input type="checkbox"/> |
|      | 32 | BROWN, et al., "Visual toxicity of synthetic retinoids", British Journal of Ophthalmology, Vol. 73, pages 286-288, 1989.   | <input type="checkbox"/> |
|      | 33 | CAFFERY, et al., "Ocular side effects of isotretinoin therapy", Journal of the American Optometric Association, Vol. 59, No. 3, pages 221-224, March 1988.   | <input type="checkbox"/> |
| ↓    | 34 | DENMAN, et al., Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne", Journal of the American Academy of Dermatology, Vol. 14, No. 4, pages 692-693, April 1986.               | <input type="checkbox"/> |

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10593261            |
| Filing Date            | 2007-07-11          |
| First Named Inventor   | Lars Michael Larsen |
| Art Unit               | 1614                |
| Examiner Name          |                     |
| Attorney Docket Number | LARSEN=5            |

|      |    |  |                          |
|------|----|--|--------------------------|
| /ZF/ | 35 | FEIST, et al., "Visual Side Effects of Isotretinoin Therapy", SOUTHERN MEDICAL JOURNAL, Vol. 80, No. 10, page 1332, October 1987.                                | <input type="checkbox"/> |
| /ZF/ | 36 | FRAUNFELDER, et al., "Adverse Ocular Reactions Possibly Associated with Isotretinoin", American Journal of Ophthalmology, Vol. 100, pages 534-537, October 1985. | <input type="checkbox"/> |
| /ZF/ | 37 | GROSS, et al., "Retinoids and the Eye", Dermatologic Clinics, Vol. 10, No. 3, pages 521-531, July 1992.  | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

|                    |                           |                 |  |
|--------------------|---------------------------|-----------------|--|
| Examiner Signature | /Zohreh Fay/ (08/29/2010) | Date Considered |  |
|--------------------|---------------------------|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.